Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01905631 · ClinicalTrials.gov registry record · Phase 2
Blinded, Randomized Study Evaluating Aurstat Versus Control in the Treatment of Atopic Dermatitis Associated Pruritus
A Phase 2 study, sponsored by The Center for Clinical and Cosmetic Research.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT01905631: Completed Phase 2 study, sponsored by The Center for Clinical and Cosmetic Research.
NCT01905631 is a Phase 2 study that has completed, run by The Center for Clinical and Cosmetic Research. The registered enrollment target is 30 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01905631, a Phase 2 study, has completed, sponsored by The Center for Clinical and Cosmetic Research.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
To demonstrate the ability of Aurstat to reduce pruritus in subjects with mild to moderate atopic dermatitis. Efficacy results will be based on subject assessment, IGA, and photographic evidence based on ordinal scales for tolerability.
Primary Outcome
The ability of Aurstat to reduce itching in those diagnosed with Atopic Dermatitis aged 12-75 years of age. Visual analog score (VAS assessment)- the VAS itch score was defined as the number of millimeters from the left side of a line (154 mm in length) that indicates their level of itching (0 mm (no itching)-154 mm (most itching)).
Interventions
- DRUG Aurstat Anti-Itch Hydrogel (Aurstat)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2013-07 |
| Est. Completion | 2013-09 |
| Phase | Phase 2 |
What the finished NCT01905631 record still lists
NCT01905631 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 1 intervention - of which Aurstat Anti-Itch Hydrogel (Aurstat) is the first listed.
NCT01905631 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01905631 about?
NCT01905631 is a clinical study titled "Blinded, Randomized Study Evaluating Aurstat Versus Control in the Treatment of Atopic Dermatitis Associated Pruritus". To demonstrate the ability of Aurstat to reduce pruritus in subjects with mild to moderate atopic dermatitis. Efficacy results will be based on subject assessment, IGA, and photographic evidence based on ordinal scales for tolerability.
What is the current status of trial NCT01905631?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2013-07. Estimated completion is 2013-09.
What interventions are being tested in trial NCT01905631?
The interventions under investigation include: Aurstat Anti-Itch Hydrogel (Aurstat) (DRUG).
Who is sponsoring clinical trial NCT01905631?
This trial is sponsored by The Center for Clinical and Cosmetic Research, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01905631's enrollment target sits among peer trials
30 1582nd of 2000 higher than 332 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia